{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:55:40Z","timestamp":1791230140441,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA016672"],"award-info":[{"award-number":["P30-CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.semradonc.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T19:22:20Z","timestamp":1694028140000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances and Challenges in Conducting Clinical Trials With Proton Beam Therapy"],"prefix":"10.1016","volume":"33","author":[{"given":"J. Isabelle","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.semradonc.2023.06.006_bib0001","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.21.02831","article-title":"Intensity-modulated radiation therapy reduces patient-reported chronic toxicity compared with conventional pelvic radiation therapy: Updated results of a phase III trial","volume":"40","author":"Yeung","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2023.06.006_bib0002","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijrobp.2013.06.2059","article-title":"Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: A prospective randomized study","volume":"87","author":"Gandhi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2023.06.006_bib0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/153303460600500202","article-title":"Clinical applications of proton radiation treatment at Loma Linda University: Review of a 15-year experience","volume":"5","author":"Slater","year":"2006","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2023.06.006_bib0004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/0284186X.2013.770167","article-title":"Establishing and expanding the indications for proton and particle therapy","volume":"52","author":"Muren","year":"2013","journal-title":"Acta Oncol"},{"issue":"6-7","key":"10.1016\/j.semradonc.2023.06.006_bib0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/07357907.2021.1944180","article-title":"Geospatial disparities in access to proton therapy in the continental United States","volume":"39","author":"Maillie","year":"2021","journal-title":"Cancer Invest"},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0006","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ijrobp.2014.04.019","article-title":"Multifield optimization intensity modulated proton therapy for head and neck tumors: A translation to practice","volume":"89","author":"Frank","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"144","key":"10.1016\/j.semradonc.2023.06.006_bib0007","first-page":"e58372","article-title":"Proton therapy delivery and its clinical application in select solid tumor malignancies","author":"Kaiser","year":"2019","journal-title":"J Vis Exp"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0008","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ijrobp.2016.01.055","article-title":"First clinical investigation of cone bone computed tomography and deformable registration for adaptive proton therapy of lung cancer","volume":"95","author":"Veiga","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.semradonc.2023.06.006_bib0009","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/PPO.0000000000000080","article-title":"The use of proton therapy in the treatment of lung cancers","volume":"20","author":"Simone","year":"2014","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2017.08.005","article-title":"Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation","volume":"125","author":"Verma","year":"2017","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijrobp.2016.03.053","article-title":"Reirradiation of head and neck cancers with proton therapy: Outcomes and analyses","volume":"96","author":"Phan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jnci\/djx208","article-title":"Quality of life and patient-reported outcomes following proton radiation therapy: A systematic review","volume":"110","author":"Verma","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2023.06.006_bib0013","unstructured":"Radiation Oncology Model, Center for Medicare and Medicaid Innovation, 2017-2019 Baseline Episode File (2017-2019) (XLS) (Link)"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2016.05.022","article-title":"Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer \u2013 a case matched analysis","volume":"120","author":"Blanchard","year":"2016","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2023.06.006_bib0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.radonc.2017.05.006","article-title":"Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer","volume":"123","author":"Zhang","year":"2017","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14338\/IJPT-15-00011.1","article-title":"Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: A case-match control study of intensity modulated proton therapy (IMPT) and intensity modulated photon therapy (IMRT)","volume":"2","author":"Holliday","year":"2015","journal-title":"Int J Part Ther"},{"issue":"2","key":"10.1016\/j.semradonc.2023.06.006_bib0017","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamaoncol.2019.4889","article-title":"Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer","volume":"6","author":"Baumann","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2023.06.006_bib0018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13014-016-0600-3","article-title":"Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: Cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy","volume":"11","author":"McDonald","year":"2016","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2023.06.006_bib0019","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2017.06.2450","article-title":"Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: A retrospective, single-institutional analysis","volume":"99","author":"Xi","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"14","key":"10.1016\/j.semradonc.2023.06.006_bib0020","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.19.02503","article-title":"Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.06.006_bib0021","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cncr.28536","article-title":"Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer","volume":"120","author":"Hoppe","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2023.06.006_bib0022","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.19.01706","article-title":"Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma","volume":"38","author":"Kahalley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2023.06.006_bib0023","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1016\/j.cllc.2021.02.002","article-title":"Single institution experience of proton and photon-based postoperative radiation therapy for non-small-cell lung cancer","volume":"22","author":"Boyce-Fappiano","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2023.06.006_bib0024","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.radonc.2015.12.008","article-title":"Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation","volume":"118","author":"Romesser","year":"2016","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ijrobp.2016.02.044","article-title":"Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: First comparative results of patient-reported outcomes","volume":"95","author":"Sio","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.14338\/IJPT-20-00067.1","article-title":"Work outcomes after intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) fro oropharyngeal cvancer","volume":"8","author":"Smith","year":"2021","journal-title":"Int J Part Ther"},{"issue":"15","key":"10.1016\/j.semradonc.2023.06.006_bib0027","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2013.04.030","article-title":"Incidence of second malignancies among patients treated with proton versus photon radiation","volume":"87","author":"Chung","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0029","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2019.01.076","article-title":"Protons versus photons for unresectable hepatocellular carcinoma: Liver decompensation and overall survival","volume":"105","author":"Sanford","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2023.06.006_bib0030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.21037\/jgo.2019.08.03","article-title":"Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: Practice patterns, outcomes, and the effect of biologically effective dose escalation","volume":"10","author":"Hasan","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0031","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2016.10.001","article-title":"National Cancer Database analysis of proton versus photon radiation therapy in non-small cell lung cancer","volume":"97","author":"Higgins","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2023.06.006_bib0032","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.radonc.2017.05.007","article-title":"Comparison of particle beam therapy and stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis","volume":"123","author":"Chi","year":"2017","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2023.06.006_bib0033","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1470-2045(14)70268-2","article-title":"Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: A systematic review and meta-analysis","volume":"15","author":"Patel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2023.06.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13205","article-title":"Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated proton therapy vs intensity-modulated radiation therapy","volume":"4","author":"Li","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijrobp.2016.02.021","article-title":"Clinical outcomes and patterns of disease recurrence following intensity modulated proton therapy for oropharyngeal squamous carcinoma: Results from a single institution prospective study","volume":"95","author":"Gunn","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0036","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(95)00063-5","article-title":"Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone","volume":"32","author":"Shipley","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.semradonc.2023.06.006_bib0037","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.semradonc.2023.06.006_bib0038","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer [published correction appears in J Clin Oncol. 2018 Aug 20;36(24):2570]","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2023.06.006_bib0039","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijrobp.2018.02.022","article-title":"Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung cancer","volume":"101","author":"Nantavithya","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.semradonc.2023.06.006_bib0040","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2023.06.006_bib0041","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/rssc.12117","article-title":"Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival","volume":"65","author":"Hobbs","year":"2016","journal-title":"J R Stat Soc Ser C Appl Stat"},{"issue":"26","key":"10.1016\/j.semradonc.2023.06.006_bib0042","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1200\/JCO.20.01405","article-title":"First randomized trial supporting the use of proton over photon chemoradiotherapy in esophageal cancer","volume":"38","author":"Simone","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0043","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2022.03.005","article-title":"Chemoradiation with hypofractionated proton therapy in stage II-III non-small cell lung cancer: A Proton Collaborative Group phase 2 trial","volume":"113","author":"Hoppe","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2023.06.006_bib0044","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijrobp.2020.03.015","article-title":"Hypofractionated proton therapy with concurrent chemotherapy for locally advanced non-small cell lung cancer: A phase 1 trial from the University of Florida and Proton Collaborative Group","volume":"107","author":"Hoppe","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2023.06.006_bib0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0000000000000241","article-title":"Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: Interim results of a randomized trial PCG GU 002","volume":"41","author":"Vargas","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0046","doi-asserted-by":"crossref","first-page":"56","DOI":"10.21037\/cco.2016.06.03","article-title":"Cost-comparativeness of proton versus photon therapy","volume":"5","author":"Verma","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0047","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13014-016-0640-8","article-title":"Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: Phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC","volume":"11","author":"Giaddui","year":"2016","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2023.06.006_bib0048","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14338\/IJPT-D-21-00004","article-title":"NRG Oncology survey of Monte Carlo dose calculation use in US proton therapy centers","volume":"8","author":"Lin","year":"2021","journal-title":"Int J Part Ther"},{"issue":"1","key":"10.1016\/j.semradonc.2023.06.006_bib0049","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.ijrobp.2011.11.072","article-title":"Prospective preference assessment of patients\u2019 willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer","volume":"83","author":"Shah","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2023.06.006_bib0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4155\/cli.14.37","article-title":"How important are willingness-to-participate studies in encouraging patient enrollment in oncology trials?","volume":"4","author":"Shah","year":"2014","journal-title":"Clin Investig. (Lond)."},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0051","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ijrobp.2018.12.019","article-title":"The insurance approval process for proton radiation therapy: A significant barrier to patient care","volume":"104","author":"Ning","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2023.06.006_bib0052","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cllc.2017.03.007","article-title":"Enrollment of elderly patients with locally advanced non-small cell lung cancer in multi-institutional trials of proton beam radiation therapy","volume":"18","author":"Verma","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2023.06.006_bib0053","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.ijrobp.2021.04.006","article-title":"Insurer's black box: Inexplicable barriers to proton therapy access for young adults","volume":"110","author":"Chhabra","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2023.06.006_bib0054","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.prro.2019.08.005","article-title":"Commercial insurance coverage of advanced radiation therapy techniques compared with American Society for Radiation Oncology model policies","volume":"10","author":"Verma","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0055","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ijrobp.2019.04.007","article-title":"The insurance approval process for proton beam therapy must change: Prior authorization is crippling access to appropriate health care","volume":"104","author":"Yu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2023.06.006_bib0056","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ijrobp.2018.12.021","article-title":"Insurance approval for proton beam therapy and its impact on delays in treatment","volume":"104","author":"Gupta","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429623000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429623000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:16:23Z","timestamp":1762355783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429623000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1053429623000437"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2023.06.006","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and Challenges in Conducting Clinical Trials With Proton Beam Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}